adegok
ao
grant
md
enhanc
human
immunodefici
virusspecif
cell
respons
heteroclit
peptid
human
immunodefici
viru
hiv
specif
cell
play
critic
role
contain
hiv
replic
delay
diseas
progress
howev
hivspecif
cell
becom
progress
exhaust
chronic
hiv
infect
proce
symptom
cell
exhaust
rang
express
inhibitori
receptor
select
loss
cytokin
product
capac
reduc
prolif
potenti
impair
differenti
effector
cell
increas
suscept
apoptosi
effect
combin
antiretrovir
therapi
cart
durabl
reduc
hiv
viremia
undetect
level
alon
restor
full
pluripot
hivspecif
cell
number
studi
subset
peptid
epitop
variant
categor
heteroclit
restimul
potent
cellular
immun
respons
vitro
nativ
immun
peptid
properti
heteroclit
peptid
exploit
experiment
cancer
chronic
viral
infect
model
promot
clearanc
transform
cell
persist
virus
review
consid
possibl
heteroclit
peptid
could
improv
efficaci
therapeut
vaccin
part
hiv
immunotherapi
erad
strategi
review
literatur
heteroclit
peptid
illustr
potenti
benefici
modul
natur
hivspecif
cell
respons
toward
found
small
minor
hivinfect
avirem
person
term
elit
control
longterm
nonprogressor
review
suggest
efficaci
hiv
vaccin
could
improv
identif
test
incorpor
heteroclit
variant
nativ
hiv
peptid
epitop
keyword
heteroclit
peptid
cell
therapeut
vaccin
hiv
epitop
introduct
sequenc
variant
nativ
refer
peptid
commonli
refer
analog
peptid
mimotop
alter
peptid
ligand
apl
variant
peptid
heteroclit
peptid
subset
sequenc
variant
stimul
stronger
cell
respons
nativ
epitop
refer
sequenc
use
primari
immun
amino
acid
aa
substitut
made
peptid
sequenc
heteroclit
peptid
presum
increas
peptid
antigen
immunogen
enhanc
peptidebind
affin
human
histocompatibilitylink
leukocyt
antigen
hla
andor
improv
cell
receptor
tcr
recognit
bound
peptid
given
thymic
cell
posit
select
ultim
base
moder
affin
tcr
bind
selfpeptid
present
cortic
epitheli
cell
concept
refer
nativ
epitop
immun
respons
aris
foreign
pathogen
pure
contextu
cell
repertoir
perspect
reactiv
individu
cell
clone
select
one
particular
peptid
entir
seri
relat
peptid
elev
tcr
interact
avid
rel
manifest
interact
origin
selfpeptid
although
address
experiment
sequenc
variant
particular
refer
nativ
wildtyp
wt
foreign
peptid
recogn
host
cell
sit
among
virtual
seri
peptid
enabl
recognit
origin
select
selfpeptid
unknown
thu
clear
theoret
rational
suggest
sequenc
variant
readili
construct
mediat
enhanc
immun
recognit
compar
empir
defin
refer
nativ
wt
foreign
peptid
find
cell
mice
immun
pigeon
cytochrom
c
made
stronger
prolif
respons
vitro
tobacco
hornworm
moth
cytochrom
c
pigeon
cytochrom
c
first
document
exampl
heteroclit
peptid
stimul
enhanc
immun
respons
subsequ
find
variou
experiment
system
reiter
semin
find
soling
et
al
certain
peptid
variant
restimul
potent
immun
respons
nativ
wt
refer
index
peptid
epitop
immun
system
actual
expos
review
focu
possibl
util
heteroclit
peptid
immunotherapi
human
immunodefici
viru
hiv
infect
cytokin
play
signific
role
orchestr
cell
develop
differenti
effector
function
surviv
sever
experiment
model
shown
heteroclit
peptid
enhanc
cell
cytokin
respons
beyond
stimul
nativ
peptid
tao
et
al
demonstr
heteroclit
peptid
stimul
cell
vitro
significantli
increas
product
interferongamma
compar
stimul
wt
peptid
salazar
et
al
found
heteroclit
variant
immunodomin
human
carcinoembryon
antigen
cea
specif
cell
epitop
ylsganlnl
trigger
increas
granulocytemacrophag
colonystimul
factor
gmcsf
level
induc
chronic
infect
hiv
develop
antigenspecif
cell
dysfunct
exhaust
often
reflect
sequenti
loss
cytokin
product
capac
first
reduc
abil
produc
follow
tumor
necrosi
factoralpha
lastli
loss
product
variant
immunodomin
hiv
gag
nef
epitop
test
vitro
gladney
et
al
enhanc
andor
product
hivspecif
cell
compar
stimul
refer
peptid
demonstr
heteroclit
properti
context
cytokin
modul
case
effect
pure
quantit
increas
number
cell
produc
also
case
variant
peptid
select
skew
cytokin
product
toward
thu
set
chronic
infect
lead
cell
exhaust
heteroclit
capac
variant
peptid
may
enhanc
nomin
cell
function
even
reconstitut
cell
function
longer
stimul
nativ
peptid
epitop
followup
experi
addit
heteroclitichiv
peptid
stimul
larger
cytokin
respons
report
gladney
et
al
identifi
test
abil
increas
cell
prolifer
reduc
phenotyp
evid
exhaust
rel
vitro
stimul
nativ
peptid
failur
contain
tumor
growth
partli
attribut
suboptim
prolifer
tumorspecif
cell
respond
poorli
immunogen
tumorassoci
antigen
taa
circumv
issu
heteroclit
peptid
variant
taa
use
expand
taareact
cell
gener
effect
antitumor
cell
respons
certain
case
power
adjuv
also
use
overcom
rel
immun
toler
taa
rel
weak
bind
selfpeptid
hla
molecul
anoth
exampl
heteroclit
peptid
enhanc
cell
prolifer
vitro
expans
cell
use
analog
autoantigen
peptid
hslgkwlghpdkf
myelin
proteolipid
protein
plp
tryptophan
w
replac
glutamin
q
posit
first
case
lead
enhanc
antitumor
respons
second
promot
autoimmun
principl
illustr
weak
cell
respons
due
part
selftoler
invigor
use
heteroclit
stimul
chronic
hiv
infect
reduc
prolifer
hivspecif
cell
progress
infect
reflect
cell
exhaust
distinct
anergi
due
selftoler
may
modul
approach
found
heteroclit
hiv
peptid
stimul
increas
hivspecif
cell
prolifer
least
rel
refer
peptid
stimul
nearli
heterocliticrefer
peptid
pair
compar
function
avid
measur
amount
antigen
peptid
requir
success
activ
trigger
effector
function
activ
cell
cell
respond
effici
low
dose
antigen
call
highavid
cell
sever
studi
indic
strong
correl
pmhc
tcr
stabil
function
cell
avid
enhanc
antitumor
cellmedi
immun
associ
loss
toler
taa
studi
use
heteroclit
taa
peptid
due
increas
pmhc
tcr
stabil
heteroclit
peptid
reflect
higher
avid
longer
interact
time
similar
effect
observ
mycoplasma
penetran
permeas
proteinderiv
peptid
iyifaacl
use
stimul
melanoma
antigen
gene
mage
cell
function
avid
cell
stimul
peptid
approxim
time
greater
cell
stimul
wt
peptid
ighvyifatclglsyd
absolut
number
hivspecif
cell
recruit
primari
hiv
infect
undoubtedli
import
hivspecif
cell
highavid
hiv
peptid
epitop
key
earli
hiv
suppress
contrast
welldocu
exampl
heteroclit
taa
peptid
induc
highavid
cell
limit
studi
highavid
cell
gener
use
heteroclit
peptid
context
hiv
infect
stimul
heteroclit
variant
hivrevers
transcriptas
rt
peptid
residu
significantli
increas
cytotox
lymphocyt
ctl
respons
nativ
pol
peptid
donor
test
comparison
stimul
nativ
pol
peptid
threefold
increas
level
hlaa
complex
surfac
antigenpres
cell
apc
puls
heteroclit
variant
thought
underli
enhanc
ctl
respons
anoth
studi
suggest
hiv
proteas
pr
peptid
lvgptpvni
act
heteroclit
variant
protein
signal
peptid
lldvptaav
activ
autoreact
cell
subset
individu
express
therefor
exposur
heteroclit
peptid
potenti
cut
way
promot
autoimmun
activ
selfreact
cell
equal
possibl
outcom
enhanc
cell
respons
foreign
tumor
antigen
recognit
kill
infect
cell
import
immunolog
effector
function
hiv
virus
critic
import
hivspecif
ctl
control
viremia
well
document
abil
upregul
product
cytotoxin
perforin
granzym
degranul
manner
releas
toward
target
cell
associ
viral
control
longterm
nonprogressor
ltnp
convers
usual
impair
rapid
progressor
rp
cytolysi
target
cell
ctl
also
mediat
fasfa
ligand
fasl
pathway
perforingranzym
releas
degranul
thought
predomin
mode
kill
infect
target
cell
hivspecif
ctl
sever
analog
hiv
rt
peptid
ilkepvhgv
test
abil
enhanc
hiv
polspecif
ctl
activ
stimul
peripher
blood
mononuclear
cell
hivinfect
individu
vitro
variant
peptid
gener
significantli
higher
wt
polspecif
ctl
activ
compar
stimul
wt
pol
peptid
ilkepvhgv
likewis
seri
subject
chronic
lymphocyt
leukemia
cll
ctl
gener
stimul
heteroclit
immunoglobulin
ig
variabl
gene
framework
region
fr
deriv
peptid
qlpgkglewv
enhanc
cytotox
apc
puls
nativ
peptid
qapgkglewv
kill
cll
cell
unpuls
apc
anoth
exampl
ctl
rais
stimul
heteroclit
peptid
klflqmnsl
effect
lyse
apc
puls
heteroclit
peptid
cll
cell
display
nativ
epitop
tlflqmnsl
ctl
gener
stimul
nativ
peptid
fail
lyse
either
apc
stimul
nativ
peptid
cll
cell
separ
studi
heterocliticvari
cell
surfac
glycoprotein
restrict
myeloid
lineag
cell
effect
gener
acut
myeloid
leukemia
aml
specif
ctl
lyse
inhibit
prolifer
normal
progenitor
cell
find
indic
heteroclit
peptid
stimul
often
gener
substanti
effect
ctl
respons
nativ
epitop
certain
situat
even
activ
autoreact
cell
way
allow
select
kill
infect
transform
cell
normal
healthi
cell
induct
stronger
durabl
higher
avid
cell
respons
could
power
aspect
prevent
therapeut
hiv
vaccin
incorpor
heteroclit
peptid
hiv
infect
chronic
express
program
molecul
hivspecif
cell
signatur
function
cell
impair
clearli
associ
diseas
progress
hivspecif
cell
elit
control
ec
ltnp
express
significantli
less
normal
fast
progressor
sever
studi
aim
improv
exhaust
cell
respons
use
monoclon
antibodi
block
either
ligand
introduc
exogen
costimulatori
molecul
case
intervent
improv
effector
function
respond
cell
extent
howev
nativ
hivpeptid
epitop
use
stimul
hivspecif
cell
instanc
suggest
even
benefit
might
deriv
use
heteroclit
peptid
recent
studi
demonstr
heteroclit
variant
nativ
hivpeptid
epitop
improv
charact
well
magnitud
hivspecif
cell
respons
rel
respons
induc
refer
epitop
even
without
introduc
exogen
costimulatori
molecul
block
inhibitori
receptor
approxim
case
test
fraction
prolifer
hivspecif
cell
express
significantli
reduc
follow
stimul
heteroclit
peptid
comparison
stimul
refer
peptid
effect
heteroclit
peptid
stimul
express
cell
exhaust
marker
studi
experiment
system
cite
possibl
improv
cell
respons
least
partial
relat
reduc
exhaust
stimul
cell
surprisingli
signific
correl
reduc
express
enhanc
prolifer
experi
carri
heteroclit
peptid
could
mean
either
heteroclit
peptid
select
distinct
heterogen
subset
hivspecif
cell
activ
signal
gener
heteroclit
peptid
stimul
somehow
bypass
signal
pathway
therebi
allow
enhanc
prolifer
even
hi
cell
figur
normal
inhibitori
signal
deliv
downregul
tcr
signal
direct
dephosphoryl
intracellular
signal
intermedi
phosphatas
associ
dephosphoryl
prevent
phosphoryl
possibl
explan
neglig
effect
signal
prolifer
hivspecif
cell
respond
heteroclit
peptid
stimul
could
increas
tyrosin
phosphoryl
tcr
chain
ctl
stimul
heteroclit
peptid
rel
nativ
peptidestimul
ctl
fact
report
studi
salazar
et
al
support
possibl
heteroclit
peptid
potenti
bypass
pathway
effect
exhaust
stimul
refer
peptid
occur
recent
public
demonstr
differenti
effect
express
hivspecif
cell
relat
tcr
clonotyp
well
epitop
specif
vivo
histori
antigen
exposur
thu
varieti
intrins
extrins
factor
modul
translat
cell
stimul
even
close
relat
peptid
rang
potenti
outcom
despit
spectacular
success
combin
antiretrovir
therapi
cart
treat
hiv
infect
remain
imposs
cure
hiv
infect
extrem
rare
case
cure
could
either
steril
erad
hivinfect
cell
infecti
viral
particl
function
longterm
suppress
hiv
replic
absenc
cart
berlin
patient
transplant
allogen
stem
cell
donor
regard
document
case
steril
cure
report
case
hiv
cure
upon
cart
cessat
visconti
cohort
mississippi
babi
repres
function
cure
unknown
know
question
durabl
viral
rebound
individu
taken
treatment
classifi
function
cure
attribut
longliv
hiv
reservoir
persist
latent
infect
cell
approach
hiv
cure
term
kick
kill
strategi
develop
overcom
challeng
pose
longliv
hiv
reservoir
approach
aim
reactiv
latent
virus
histon
deacetylas
inhibitor
agent
kick
expos
reactiv
virus
infect
cell
hivspecif
immun
andor
cart
kill
concern
rais
capac
endogen
ctl
recogn
mediat
effector
function
efficaci
requir
extinguish
reactiv
hiv
sung
et
al
show
vitro
restimul
expans
endogen
antihiv
ctl
produc
effector
cell
target
latent
reservoir
either
vivo
vitro
restimul
antihiv
ctl
defin
heteroclit
peptid
concert
kick
approach
reactiv
latent
viru
reservoir
could
enhanc
capac
antihiv
ctl
effect
target
reactiv
viru
potenti
heteroclit
peptid
gener
higher
avid
crossreact
ctl
help
purg
escap
variant
significantli
contribut
residu
viremia
previous
document
murin
hepat
viru
mhv
infect
two
mhv
strain
jhm
jhmv
deriv
ctl
epitop
cslwngphl
rcqifani
shown
induc
highand
lowmagnitud
cell
respons
respect
select
escap
mutant
chronic
mhvinfect
mice
immunodomin
epitop
gener
highavid
ctl
respons
wherea
approxim
lower
avid
cell
respons
gener
subdomin
epitop
improv
cell
respons
butler
et
al
substitut
tyrosin
residu
glutamin
posit
peptid
sequenc
rcyifani
approxim
nativ
peptid
requir
reach
respons
level
induc
heteroclit
peptid
immun
effect
protect
diseas
progress
context
ctl
escap
mutat
enhanc
clearanc
mhv
thu
heteroclit
peptid
could
effect
ctl
escap
chronic
hiv
infect
also
benefici
kick
kill
approach
hiv
cure
unlik
prophylact
vaccin
provid
uninfect
person
protect
invad
pathogen
therapeut
treatment
vaccin
design
modul
ongo
immun
respons
unresolv
infect
chronic
condit
therapeut
vaccin
gener
engin
induc
cellmedi
rather
humor
immun
enhanc
exist
gener
new
immun
respons
toward
chronic
pathogen
tumor
antigen
hivinfect
individu
strong
ctl
respons
primari
phase
infect
chronic
infect
ensu
least
part
due
abil
viru
escap
effect
recognit
hivspecif
cell
thu
viral
persist
reflect
ineffici
recognit
hiv
escap
mutant
preced
function
impair
hivspecif
cell
although
cart
dramat
reduc
morbid
mortal
among
individu
chronic
hiv
infect
hivspecif
cell
dysfunct
persist
success
art
treatment
leav
immun
system
compromis
state
addit
high
cost
pill
burden
requir
strict
adher
side
effect
drawback
limit
univers
applic
cart
contain
hiv
epidem
econom
burden
impos
hiv
epidem
develop
develop
world
alreadi
hinder
growth
econom
reason
alon
urgent
need
explor
altern
cart
immunebas
strategi
reduc
requir
lifetim
cart
eas
associ
physiolog
econom
burden
potenti
heteroclit
variant
previous
gener
use
tumorassoci
peptid
hepat
b
viru
hbv
peptid
hiv
regardless
length
variant
peptid
heteroclit
activ
either
conserv
semiconserv
aa
substitut
posit
decreas
amount
peptid
requir
trigger
cell
respons
infer
structur
xray
crystallographi
pmhc
tcr
complex
reveal
side
chain
aa
posit
peptid
bound
mhc
molecul
interact
directli
complementar
determin
region
tcr
chain
tabl
aa
similar
score
use
studi
sett
et
al
deriv
averag
rank
coeffici
score
toler
point
mutat
within
protein
estim
dayhoff
point
accept
mutat
pam
matrix
hydrophob
calcul
averag
kytedoolittl
faucherepliska
scale
estim
hydrophob
hydrophil
respect
aa
side
chain
volum
measur
displac
aa
pair
later
shown
heteroclit
variant
hiv
nativ
peptid
epitop
gener
manner
similar
illustr
sett
et
al
use
tabl
select
juli
volum
articl
enhanc
cell
respons
frontier
immunolog
wwwfrontiersinorg
conserv
semiconserv
aa
substitut
posit
nativ
peptid
epitop
potenti
barrier
develop
gener
heteroclit
peptid
therapeut
vaccin
hiv
includ
inher
individu
divers
hla
class
genotyp
tcr
repertoir
plu
differenti
immunolog
respons
reflect
variabl
impact
hiv
infect
experi
hivinfect
individu
respond
wt
peptid
often
demonstr
heteroclit
respons
variant
peptid
thu
heteroclit
peptid
vaccin
would
need
individu
design
least
initi
optim
approach
vaccin
overal
invest
prohibit
compar
drug
resist
viral
tropism
test
consid
term
potenti
reduc
antiretrovir
depend
contribut
hiv
cure
individu
would
requir
map
hivspecif
cell
respons
standard
method
first
avail
overlap
peptid
pool
subsequ
deconvolut
matric
epitop
would
select
investig
amongst
identifi
base
immunodomin
polyfunction
respond
cell
term
cytokin
product
semisystemat
approach
gener
candid
heteroclit
peptid
make
conserv
semiconserv
aa
substitut
posit
probabl
improv
use
populationbas
hiv
sequenc
data
sort
hla
genotyp
analysi
data
indic
site
immun
select
estim
hierarchi
identifi
put
adapt
escap
mutat
importantli
nonadapt
exclud
aa
particular
site
within
ctl
epitop
like
exclud
due
enhanc
immunogen
sequenc
although
seem
counterintuit
may
exactli
sequenc
select
avoid
hiv
context
certain
hla
molecul
rather
broadli
conserv
sequenc
effect
immunogen
hiv
larg
seri
variant
peptid
epitop
common
popul
could
synthes
test
vitro
heteroclit
properti
ideal
heteroclit
peptid
activ
higher
fraction
cell
stimul
polyfunct
respons
increas
cell
prolifer
drive
differenti
fulli
function
effector
cell
equal
superior
tcr
recognit
nativ
peptid
exist
variant
individu
vitro
test
heteroclit
function
reduc
risk
administ
peptid
partial
agonist
antagonist
function
actual
impair
cell
respons
hiv
vivo
higher
frequenc
vitro
respons
necessarili
translat
effect
respons
vivo
vaccin
heteroclit
peptid
deriv
elagigiltv
melana
eaagigiltv
higher
affin
hla
induc
twice
frequenc
peptidereact
cell
vaccin
natur
peptid
howev
analysi
respond
cell
clonal
level
indic
mark
prefer
recognit
heteroclit
peptid
natur
peptid
recognit
lower
peptid
concentr
due
increas
affin
hla
thu
tcr
recognit
efficaci
may
overestim
term
abil
mediat
effector
function
target
cell
present
natur
peptid
choos
heteroclit
peptid
aa
modif
tcr
interact
site
affect
hlabind
affin
may
allow
unbias
comparison
tcr
recognit
effici
vitro
risk
activ
autoreact
cell
must
measur
potenti
benefit
heteroclit
vaccin
hiv
infect
imposs
comprehens
test
autoreact
selfantigen
present
cell
use
cell
avail
peripher
blood
autoreact
could
also
test
broad
panel
cell
line
express
hla
class
antigen
present
heteroclit
peptid
variant
identifi
one
suitabl
heteroclit
peptid
identifi
could
administ
individu
togeth
long
synthet
peptid
subcutan
inject
approv
adjuv
subject
would
monitor
enhanc
cell
respons
hiv
follow
vaccin
purpos
review
highlight
potenti
advantag
incorpor
heteroclit
peptid
therapeut
vaccin
particular
therapeut
hiv
vaccin
heteroclit
peptid
stimul
shown
produc
benefici
immun
respons
number
chronic
infect
diseas
model
tabl
chang
subtl
singl
conserv
aa
substitut
within
nativ
peptid
epitop
sequenc
improv
cell
respons
form
enhanc
cytokin
product
increas
prolifer
also
produc
higheravid
cell
respons
effect
ctl
kill
protect
ctl
escap
elimin
chronic
infect
specif
abrog
selftoler
elicit
antitumor
immun
prevent
revers
cell
exhaust
peptidebas
vaccin
heteroclit
peptid
immunotherapi
pose
risk
genet
integr
recombin
dna
vaccin
risk
develop
virul
reassort
revers
virul
wt
virus
attenu
viru
vaccin
henc
administr
heteroclit
peptid
except
safe
potenti
effect
mode
vaccin
heteroclit
peptidebas
vaccin
could
commerci
produc
larg
scale
low
cost
afford
poor
nation
plagu
hiv
epidem
potenti
benefit
immunotherapi
heteroclit
peptid
vaccin
formul
also
store
lyophil
form
therebi
avoid
need
coldchain
mainten
storag
transport
distribut
consequ
made
readili
avail
remot
intemper
locat
mani
demonstr
practic
theoret
advantag
heteroclit
peptid
suggest
research
inclus
therapeut
hiv
vaccin
warrant
